Research output per year
Research output per year
Personal profile
Headline
CLINICAL PROFESSOR
Fingerprint
Dive into the research topics where Howard Fillit is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Biomarkers in Alzheimer's disease clinical trials: 2025
Osse, A. M. L., Zhou, Y., Kinney, J. W., Hooyman, A., Sengupta, A., Fonseca, J., Burstein, A. H., Owen, M., Nisenbaum, L., Fillit, H. M., Cheng, F. & Cummings, J. L., 1 Jan 2026, In: Alzheimer's and Dementia: Translational Research and Clinical Interventions. 12, 1, e70217.Research output: Contribution to journal › Review article › peer-review
Open Access8 Scopus citations -
Plasma p-tau217 and glucose metabolism correlate in neocortical association areas in Alzheimer's disease
Koenig, L. N., Huber, H., Chongtham, A., Di Molfetta, G., Andrews, R. D., Lukic, A., Shafiian, N., Fillit, H. M., Blennow, K., Ashton, N. J., Zetterberg, H., Matthews, D. C. & Pereira, A. C., 2026, In: Brain Communications. 8, 2Research output: Contribution to journal › Article › peer-review
Open Access -
Add-on combination therapy with monoclonal antibodies: Implications for drug development
Cummings, J., Burstein, A. H. & Fillit, H., Dec 2025, In: Journal of Prevention of Alzheimer's Disease. 12, 10, 100359.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
Alzheimer Combination Therapies: Overview and Scenarios
Cummings, J. L., Burstein, A. H. & Fillit, H., Dec 2025, In: Journal of Prevention of Alzheimer's Disease. 12, 10, 100328.Research output: Contribution to journal › Article › peer-review
Open Access18 Scopus citations -
Biomarkers
Fillit, H. M., 1 Dec 2025, In: Alzheimer's and Dementia. 21, p. e102911Research output: Contribution to journal › Review article › peer-review
Open Access
Press/Media
-
-
FDA Approves Weekly At-Home Injection of Leqembi for Alzheimer's Patients Starting Treatment
20/07/26
1 item of Media coverage
Press/Media
-
FDA Approves LEQEMBI IQLIK® (Lecanemab-Irmb) Subcutaneous Injection As An Initiation Dose For Early Alzheimer's Disease
13/07/26 → 15/07/26
41 items of Media coverage
Press/Media
-
FDA Approves Subcutaneous Alzheimer’s Treatment by Eisai and Biogen
15/07/26
1 item of Media coverage
Press/Media
-
Eisai And Biogen's SC LEQEMBI IQLIK Wins FDA Approval For Early Alzheimer's Disease
14/07/26
1 item of Media coverage
Press/Media